Joan Connolly
Director Técnico/Científico/I+D en ALBIREO PHARMA, INC. .
Cargos activos de Joan Connolly
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ALBIREO PHARMA, INC. | Director Técnico/Científico/I+D | 13/04/2021 | - |
Historial de carrera de Joan Connolly
Antiguos cargos conocidos de Joan Connolly.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - | - |
Formación de Joan Connolly.
Queen's University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Canadá | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Joan Connolly
- Experiencia